Compare DexCom, Inc. (DXCM) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? DexCom, Inc. trades at $90.64 (market cap $33.79B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $123.16. Which is the better fit depends on your goals.
| DXCM | QQQE | |
|---|---|---|
Market Cap | $33.79B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $89.53 | $122.72 |
52-Week Low | $54.84 | $96.06 |
Enterprise Value | $33.24B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
QQQE (Direxion NASDAQ-100 Equal Weighted Index ETF) trades at $123.14, up 0.81% with a bullish technical signal from moving averages. The ETF provides equal-weighted exposure to Nasdaq-100 companies, reducing concentration risk compared to market-cap weighted alternatives. Recent news highlights SpaceX's potential inclusion in the index, which could drive additional inflows. Technical indicators show strong momentum with ADX readings above 25, though RSI suggests some overbought conditions near-term.
The equal-weight approach offers defensive positioning against tech concentration risks while maintaining Nasdaq growth exposure. Key catalysts include continued tech sector strength and index rebalancing benefits. Risks involve Nasdaq volatility and potential sector rotation away from growth stocks. The ETF's structure provides diversification benefits for investors seeking balanced Nasdaq exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
